NASDAQ:SIBNSI-Bone Stock Price, Forecast & News

SI-Bone's stock was trading at $15.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SIBN stock has increased by 31.6% and is now trading at $20.16.
View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SI-Bone in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for SI-Bone.

SI-Bone is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for SI-Bone.

SI-Bone Inc (NASDAQ:SIBN) issued its quarterly earnings data on Monday, August, 3rd. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.20. SI-Bone had a negative return on equity of 51.27% and a negative net margin of 68.27%.
View SI-Bone's earnings history.

6 equities research analysts have issued 1 year price objectives for SI-Bone's stock. Their forecasts range from $22.00 to $27.00. On average, they anticipate SI-Bone's share price to reach $24.50 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price.
View analysts' price targets for SI-Bone.

News articles about SIBN stock have trended very positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. SI-Bone earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
View the latest news about SI-Bone.

SI-Bone saw a increase in short interest in July. As of July 15th, there was short interest totaling 1,010,000 shares, an increase of 54.4% from the June 30th total of 654,100 shares. Based on an average trading volume of 170,300 shares, the days-to-cover ratio is currently 5.9 days. Approximately 4.7% of the shares of the company are short sold.
View SI-Bone's Current Options Chain.

Some companies that are related to SI-Bone include Cantel Medical (CMD), Glaukos (GKOS), AtriCure (ATRC), Shockwave Medical (SWAV), Silk Road Medical (SILK), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Atrion (ATRI), Cerus (CERS), GenMark Diagnostics (GNMK), Cardiovascular Systems (CSII), Orthopediatrics (KIDS), Vapotherm (VAPO), OraSure Technologies (OSUR) and Cryolife (CRY).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-Bone investors own include Honeywell International (HON), CVS Health (CVS), Home Depot (HD), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO), CSX (CSX), Altria Group (MO) and Procter & Gamble (PG).

(SIBN) raised $84 million in an initial public offering (IPO) on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

SI-Bone trades on the NASDAQ under the ticker symbol "SIBN."

SI-Bone's stock is owned by many different institutional and retail investors. Top institutional investors include Swiss National Bank (0.17%), Columbus Circle Investors (0.09%), Trexquant Investment LP (0.09%), New York State Common Retirement Fund (0.08%), SG Americas Securities LLC (0.05%) and UBS Group AG (0.03%). Company insiders that own SI-Bone stock include Anthony J Recupero, David P Bonita, Jeffrey W Dunn, Laura Francis, Mark A Reiley, Michael A Pisetsky, Scott A Yerby, Skyline Venture Partners V Lp and W Carlton Reckling.
View institutional ownership trends for SI-Bone.

SIBN stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, and UBS Group AG. Company insiders that have sold SI-Bone company stock in the last year include Anthony J Recupero, Jeffrey W Dunn, Laura Francis, Michael A Pisetsky, Scott A Yerby, Skyline Venture Partners V Lp, and W Carlton Reckling.
View insider buying and selling activity for SI-Bone.

SIBN stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank, SG Americas Securities LLC, Trexquant Investment LP, New York State Common Retirement Fund, and Ameritas Investment Partners Inc.. Company insiders that have bought SI-Bone stock in the last two years include David P Bonita, and Skyline Venture Partners V Lp.
View insider buying and selling activity for SI-Bone.

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of SIBN stock can currently be purchased for approximately $20.16.

SI-Bone has a market capitalization of $577.18 million and generates $67.30 million in revenue each year. The company earns $-38,400,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. SI-Bone employs 183 workers across the globe.

The official website for SI-Bone is www.si-bone.com.

SI-Bone's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at 408-207-0700 or via email at [email protected]